ArticleBiomedicines2026
Very High vs. High Tumor Mutational Burden Across Tumors: Real-World Associations with MSI, Pathway Features, and Immunotherapy Outcomes.
Maria Fernanda Teixeira, Victoria Tomaz, Lucas Campos Barbosa E Silva, Uelson Donizete, Francisco Tustumi, Helder Imoto Nakaya, Juliana Rodrigues Beal, Fernando Moura, Mitesh J Borad, Paulo Vidal Campregher and 1 more
Abstract read
In one paragraphArticle in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Maria Fernanda TeixeiraCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.ORCID 0009-0000-1202-2838 Victoria TomazCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.
Lucas Campos Barbosa E SilvaCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.
Uelson DonizeteCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.
Francisco TustumiCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.ORCID 0000-0001-6695-0496 Helder Imoto NakayaCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.ORCID 0000-0001-5297-9108 Juliana Rodrigues BealCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.
Fernando MouraCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.
Mitesh J BoradMayo Clinic Cancer Center, Phoenix, AZ 85054, USA.
Paulo Vidal CampregherCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.
Pedro Luiz Serrano Uson JuniorCenter for Personalized Medicine, Hospital Israelita Albert Einstein, São Paulo 05652900, Brazil.ORCID 0000-0001-6122-1374 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
biomarkersimmune checkpoint inhibitorsmicrosatellite instabilitypathway analysisprecision oncologytumor mutational burden
Identifiers
PMID41898240
PMCPMC13024517
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390